15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $41M | -$3M | 62.3% | -7.2% | -15.5% | -9.4% | -$470112 | — | $9M |
| 2024 | $34M | -$6M | 63.4% | -19.2% | -36.1% | -22.3% | -$2M | — | $10M |
| 2023 | $29M | -$14M | 58.6% | -36.0% | -67.5% | -48.3% | -$6M | — | $11M |
| 2022 | $28M | -$9M | 55.1% | -38.6% | -27.6% | -20.5% | -$8M | — | $17M |
| 2021 | $23M | -$5M | 58.6% | -29.9% | -12.5% | -11.0% | -$5M | — | $25M |
| 2020 | $24M | -$1M | 61.8% | -5.2% | -3.4% | -3.0% | -$2M | — | $27M |
| 2019 | $23M | $564349 | 64.1% | 2.5% | 5.0% | 4.1% | $119446 | — | $6M |
| 2018 | $17M | $910570 | 62.3% | 6.7% | 10.2% | 8.6% | $1M | — | $4M |
| 2017 | — | $904957 | — | — | 11.8% | 9.8% | $762095 | — | $4M |
| 2017 | — | -$534999 | — | — | -8.0% | -6.5% | — | — | $3M |
| 2016 | — | $782864 | — | — | 11.0% | 9.3% | — | — | $4M |
| 2015 | — | $753117 | — | — | 12.0% | 10.3% | — | — | $3M |
| 2014 | — | $703429 | — | — | 13.5% | 11.3% | — | — | $2M |
| 2013 | — | $725763 | — | — | 16.7% | 13.0% | — | $439306 | $2M |
| 2012 | — | $815893 | — | — | 23.0% | 17.0% | — | $482800 | $2M |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $12M | $252449 | 65.1% | 5.2% | 1.4% | 0.9% | $108206 | — | $8M |
| Mar '26 | $12M | -$807078 | 61.5% | -7.4% | -4.8% | -2.8% | -$31500 | — | $9M |
| Dec '25 | $11M | -$486856 | 62.6% | -5.0% | -2.9% | -1.7% | $686974 | — | $9M |
| Sep '25 | $10M | -$777966 | 60.2% | -8.3% | -4.7% | -2.9% | $12973 | — | $8M |
| Jun '25 | $10M | -$206867 | 63.5% | -3.1% | -1.3% | -0.8% | -$489154 | — | $8M |
| Mar '25 | $10M | -$1M | 62.8% | -12.9% | -7.1% | -4.3% | -$680905 | — | $9M |
| Dec '24 | $9M | -$2M | 62.9% | -18.0% | -9.3% | -5.7% | $983182 | — | $10M |
| Sep '24 | $8M | -$2M | 63.4% | -20.8% | -8.9% | -5.8% | -$2M | — | $9M |
| Jun '24 | $8M | -$988715 | 65.0% | -14.1% | -5.3% | -3.6% | -$112949 | — | $10M |
| Mar '24 | $8M | -$2M | 62.3% | -23.9% | -10.1% | -7.0% | -$479803 | — | $11M |
| Dec '23 | $7M | -$7M | 60.3% | -30.6% | -36.7% | -26.2% | $900753 | — | $11M |
| Sep '23 | $7M | -$1M | 62.0% | -25.6% | -5.0% | -3.9% | -$1M | — | $11M |
| Jun '23 | $7M | -$2M | 56.1% | -46.5% | -8.9% | -6.9% | -$256578 | — | $12M |
| Mar '23 | $7M | -$2M | 56.1% | -41.3% | -8.1% | -6.3% | -$5M | — | $12M |
| Dec '22 | $7M | -$2M | 55.5% | -34.2% | -6.3% | -4.7% | $1M | — | $17M |
| Sep '22 | $8M | -$1M | 55.7% | -19.7% | -3.8% | -2.9% | -$3M | — | $16M |
| Jun '22 | $7M | -$3M | 51.1% | -55.2% | -9.0% | -6.9% | -$4M | — | $18M |
| Mar '22 | $6M | -$3M | 58.0% | -50.1% | -7.3% | -5.8% | -$3M | — | $23M |
| Dec '21 | $6M | -$1M | 59.0% | -32.6% | -2.9% | -2.6% | -$761590 | — | $25M |
| Sep '21 | $6M | -$1M | 57.9% | -21.9% | -3.0% | -2.6% | -$975725 | — | $26M |
How the market has priced KRMD against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, KORU Medical Systems, Inc.'s revenue has grown 11.2% per year. These are computed facts, not advice.
As of FY2025, KORU Medical Systems, Inc. reported — of total debt against $9M of cash.
In FY2025, gross margin was 62.3%, operating margin -7.2%, and net margin -6.4%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.